Cambridge, MA, United States of America

Thomas Knight

This inventor holds 3 USPTO granted patents. Top assignee: Massachusetts Institute of Technology. Active years: 2016-2018.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Thomas Knight: Innovator in Bioengineering

Introduction

Thomas Knight is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of bioengineering, particularly in the development of programmable logic devices for biological applications. With a total of 3 patents, Knight's work is at the forefront of innovation in synthetic biology.

Latest Patents

Knight's latest patents include the "Bio-field programmable gate array" and "Bio-programmable logic array: reconfigurable chassis construction." These inventions focus on reconfigurable chassis that allow for rapid construction and optimization of biocircuits. Additionally, he has developed methods for the rapid assembly of multiple arbitrary length DNA fragments, which relate to the composition and methods for isolating and assembling DNA molecules without intermediate cloning steps.

Career Highlights

Knight is affiliated with the Massachusetts Institute of Technology, where he continues to push the boundaries of bioengineering. His work has garnered attention for its potential applications in various fields, including medicine and biotechnology.

Collaborations

Some of his notable coworkers include Jonathan William Babb and Ron Weiss, who have collaborated with Knight on various projects within the realm of synthetic biology.

Conclusion

Thomas Knight's innovative work in bioengineering and synthetic biology exemplifies the potential of technology to transform biological research and applications. His contributions continue to inspire advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…